A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration

Trial Profile

A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2017

At a glance

  • Drugs DE 120 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Santen Incorporated
  • Most Recent Events

    • 12 May 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jan 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov.
    • 28 Jan 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top